

## Evidence of biological mechanisms and health predictions: an insight into clinical reasoning

Saúl Pérez-González<sup>1</sup> and Elena Rocca<sup>2</sup>

1 University of Turin. [saul.perezgonzalez@unito.it](mailto:saul.perezgonzalez@unito.it)

2 Oslo Metropolitan University. [elenaroc@oslomet.no](mailto:elenaroc@oslomet.no)

### Abstract

Traditionally, the understanding of biological mechanisms has played a central role in clinical reasoning. With the rise of the evidence-based paradigm, however, this role has come under scrutiny. On the one hand, clinical guidelines now place less emphasis on the evidence of pathophysiological mechanisms – a shift motivated by the unreliability of our understanding of complex biological mechanisms. On the other hand, some scholars defend evidence of mechanisms as crucial for clinical practice. Here, we assess the relevance of evidence of biological mechanisms in two types of clinical predictions: predictions about the efficacy and about the safety of a certain intervention for a particular patient. For each type of prediction, we will analyse separately the two roles that evidence of mechanisms might have—confirming and disconfirming—depending on whether or not it supports that certain epidemiological results apply to the single patient. We argue that the ‘unreliability because of incompleteness’ argument against the emphasis on mechanistic clinical thinking only applies to some of the considered cases. We conclude by offering a model for a more granular view of the role that evidence of mechanisms should play in clinical practice.

### Keywords

Clinical practice; Evidence; Mechanism; Efficacy; Safety.

### 1 Introduction

In clinical practice, it is necessary to make evidence-based decisions about which interventions will be most beneficial to the patient. To this end, one needs to use the best available evidence to predict the outcomes of the available interventions in the patient. However, this is not a straightforward task. Indeed, in evidence-based medicine (EBM) there is a disagreement about the type of evidence required to make reliable predictions about the outcomes of available interventions for individual patients. The dominant EBM paradigm emphasises evidence of difference-making, meaning that high-quality randomised controlled studies are generally considered the best scientific ground for predicting the outcome of a certain intervention (Howick 2011a). As a consequence, the majority of clinical guidelines de-emphasise evidence of biological mechanisms in favour of evidence of difference-making derived from population studies. As evidence of this trend, expert panels in charge of writing guidelines increasingly focus on evaluating the quality of statistical analyses and the experimental design of clinical studies, while the number of topical experts participating on these panels is decreasing (Giorgi Rossi 2016). In opposition to this paradigm, many authors have argued that evidence of mechanisms is often crucial when using population studies to make accurate predictions about a target population or an individual patient (Clarke et al. 2014; Parkkinen et al. 2018; Rocca 2016; Russo and

Williamson 2007; Williamson 2019). Evidence of mechanisms is understood as the evidence of either the existence of mechanisms or their features in the domain of inquiry (Illari 2011). There is no specific evidence-gathering method through which evidence of mechanisms must be obtained. A wide variety of methods are considered adequate, including case reports, autopsies, and cohort studies. In that framework, a broad view of mechanisms is usually adopted. A mechanism can be a complex system (Illari and Williamson 2012), a causal process (Salmon 1998), or some combination of both. Since it is beyond our scope to advocate for one particular characterisation of mechanisms, we are going to follow the broad approach to the notion of mechanism.<sup>1</sup>

In this paper, we aim to offer an analysis of the precise role that evidence of mechanisms should play in clinical reasoning. In particular, we will look at the significance of mechanistic evidence for the cases in which a clinician needs to evaluate the relevance of epidemiological results for a single patient. Note that it is not our aim to argue for the importance of evidence of mechanisms within clinical practice, which has already been highlighted by previous analyses (Andersen 2012; Tonelli and Williamson 2020). These analyses show that, in certain contexts, evidence of mechanisms can even offer a sufficient basis for reliable predictions about the outcomes of interventions in individual patients. Here, we acknowledge such arguments, and we aim to push the discussion one step further. Indeed, it has not yet been specified *how relevant* evidence of mechanisms could be for clinical practice and *when* it could offer sufficient bases for reliable predictions. Filling this gap is the aim of this paper. In order to address those questions, we will divide the general issue into different scenarios. Each scenario is characterised by the distinct role that mechanistic evidence plays. In this sense, we will follow the approach adopted by Pérez-González and Iranzo (2021) in their discussion of mechanism-based causal extrapolation from a study population to a target population of interest. In their analysis, the authors distinguish between a ‘positive’, or confirming, and a ‘negative’, or disconfirming, role for evidence of mechanisms, depending on whether it supports or undermines a causal extrapolation. In the positive, or confirming, scenario, the relevant mechanisms at work in the study and the target population are similar in their relevant aspects. The extrapolation of the causal claim is thus justified. In the negative, or disconfirming, scenario, the relevant mechanisms at work in the study and the target population differ in their relevant aspects, making the extrapolation of the causal claim not justified. The authors take this distinction as a reference and argue that evidence of mechanisms is not equally relevant in both scenarios. While the disconfirming role of evidence of mechanisms is highly reliable, the confirming role faces important difficulties and additional evidence is required to support the extrapolation of a causal claim. Here, we apply a similar approach to the clinical setting, where the extrapolation needs to be made from epidemiological data (experiments, observational studies, other patients) to one single patient.

## **2 Two kinds of prediction**

Wise clinical choices must involve two kinds of prediction about the outcomes of the available interventions: predictions about efficacy and predictions about safety. Clinicians, indeed, are not only interested in whether the intervention will produce the desired (targeted) effect in a particular patient but must also consider whether it will cause relevant side (untargeted) effects. Here, we are going to treat predictions about the efficacy and about the safety of interventions separately for two main reasons.

First, the target effect is one (or few) and known, while untargeted effects are many and often unknown. This asymmetry demands different standards of evidence for the efficacy and safety of interventions (Osimani 2013).

Second, there is a difference regarding the specificity of the research question in predictions about efficacy and in predictions about safety. When predicting efficacy, the question is usually whether the intervention is likely to produce a *specific* effect in the patient. In this case, it is often sufficient that the patient presents a single *relevant*<sup>2</sup> difference from the population average for the confidence in efficacy to drop. For example, we might wonder whether a proton pump inhibitor (PPI) will relieve symptoms of stomach acidity in the patient, given that it worked in a certain experimental group. Suppose that the patient has visceral sensitivity. If patients with this condition were excluded from the experiment, this piece of information alone would significantly decrease our expectations for achieving effects in the patient comparable to the population average, since decreasing acidity might not be sufficient to relieve the symptoms in an extra-sensitive patient.

On the contrary, when predicting safety, the question is less specific: will the intervention produce *any* undesired effect in the patient? In the previous example, suppose that the clinical trial for efficacy of PPI included a subpopulation of older patients, and that some of these patients in the experimental group developed pneumonia. Say that this is interpreted as a side-effect of the PPI, since reduced stomach acidity leads to reduced defence against bacterial infections. If we do not find any evidence of a mechanism for a vulnerable immune system (older age, chronic illness, use of immunosuppressant medicines) in our patient, we will probably not predict a high risk of—in this case—pneumonia (or other serious infections). However, the risk of a milder bacterial infection, especially for long-term therapies, should not be excluded. In addition, we would still need to evaluate whether reduced stomach acidity could have other consequences in this patient in the long run, such as fractures because of reduced calcium uptake, rebound symptoms after discontinuation, or even other unexpected effects. We see then that, given the presence of hazardous mechanisms in the experimental population, identifying one or a few relevant differences in the patient is not sufficient for concluding the absence of side effects. Those differences could modify the side effects, but they would probably still be undesired effects. Knowing *one or a few* differences might, at best, tell us that the predisposition of the patient to experience *one or a few of all the possible* untargeted effects is different than average.

There is one more clarification we need to make. One might observe that, sometimes, clinicians also need to make mechanism-based predictions about *specific* side effects. Returning to the previous example, if the patient using PPI is a post-menopausal woman, we should specifically worry about the decreased calcium uptake and increased risk of fractures. This is because the patient would already be predisposed to calcium loss and osteoporosis, given the hormonal phase she is undergoing. In this and similar cases, we are not primarily interested in whether the intervention is safe *in general*, but whether the intervention would produce a certain, *specific*, untargeted effect on the patient. In this sense, mechanism-based predictions about one precise side effect fall into the same *biological* category as predictions about efficacy. The difference with paradigmatic examples of predictions about efficacy is that the considered effect is undesired. Nonetheless, as we shall see in section 4, the ‘desired-undesired’ distinction is crucial for defining the role of evidence of mechanisms in clinical predictions.

Predictions about specific side effects and predictions about safety are of course related. If, given the presence of a mechanism through which an intervention produces a specific side effect, we assess that the intervention might produce that side effect in the patient, we must conclude that the intervention is not safe for her. The prediction of a side effect, thus, is equal to the absence of safety. Nevertheless, the opposite does not hold. Assessing that the intervention will not produce a specific side effect in the patient does not imply its safety. In the above example, even if the risk of reduced calcium uptake is identified and monitored, this does not necessarily mean that PPI are safe for the patient, in a general sense. The question about safety is a broader one,

since it asks whether the patient will be unhurt, or not hurt in a way that is considered serious or relevant. This is a complex question, as the multitude of possible effects produced by a substance depends in great part on the many combinations produced in the encounter with other entities (Rocca, Anjum, and Mumford 2020; Ruthenberg 2016).

### **3 Predictions about efficacy**

In mechanism-based predictions about efficacy from a population study to a single patient, the situation seems to be parallel to the one faced in the causal extrapolation to a target population (see section 1). Evidence of mechanisms is more reliable for determining that a causal relation does not hold in the patient (disconfirming role) than for establishing that a causal relation holds (confirming role). In this section, we will address separately the distinct roles played by evidence of mechanisms in predictions about efficacy.

#### ***3.1 Confirming predictions about efficacy***

Evidence of mechanisms may support the extrapolation of an efficacy claim from a population study to a particular patient. The confirming role of evidence of mechanisms in predictions about efficacy could be characterised as follows: if the relevant mechanisms at work in the study population and the patient are highly similar in their relevant aspects, we can conclude that the intervention will produce the targeted effect in the patient.

The confirming role of evidence of mechanisms in predictions about efficacy faces important difficulties:

- i There is no unproblematic procedure for identifying the degree of similarity between the relevant mechanisms. Comparative process tracing and alternative procedures for comparing the relevant mechanisms have been highly criticized (Howick et al. 2013; van Eersel, Koppenol-Gonzalez, and Reiss 2019). It has been argued that they are usually unfeasible. In order to establish the degree of similarity, those procedures require information about the relevant mechanisms (e.g., detailed information about their components) that is rarely available.
- ii Our knowledge about the relevant mechanisms at work in the study population and in the particular patient is usually very fragmentary (Howick et al. 2013; Reiss 2010; van Eersel, Koppenol-Gonzalez, and Reiss 2019). Even when a mechanism is identified, many of its components remain unknown. Furthermore, it is not always the case that careful studies designed to identify the relevant mechanisms at work in the patient can be conducted (e.g., emergency surgeries).
- iii In the individual patient, there may be unknown interfering mechanisms that influence the outcome (Clarke et al. 2014; van Eersel, Koppenol-Gonzalez, and Reiss 2019). Even if mechanisms similar to the relevant mechanisms identified in the study population are present in the individual patient, there may also be other relevant mechanisms. Those interfering mechanisms could even interfere with the identified mechanisms and mask or modify their own contribution to the outcome.
- iv Similar mechanisms may be present in the study population and the particular patient but not behave in a similar way (Howick et al. 2010; Howick et al. 2013; van Eersel, Koppenol-Gonzalez, and Reiss 2019). The behaviour of mechanisms may change depending on the context. Even if the relevant mechanisms at work in the study population and the patient are highly similar, they may have unanticipated and paradoxical effects in the latter.

Nevertheless, within the general problematics of this scenario, it is possible to differentiate types of situations. Confirming mechanism-based predictions about efficacy are more reliable in

some cases than in others. For instance, a mechanism-based prediction about whether a general anaesthetic will work in a patient will be more reliable than a mechanism-based prediction about whether a certain anti-proliferative drug will work against her cancer. The reason is that some mechanisms are ‘general’ enough to make problems (i) and (iv) barely relevant. In order to illustrate that idea, let us discuss an example about inhalation anaesthetic (IA). Suppose that we have to evaluate whether a certain IA will work on a specific patient who is not well-represented by any subpopulation in the available trials. Say, for instance, that she is an obese and diabetic patient. How reliable would a mechanism-based prediction about the efficacy of the intervention be?

IAs work by reducing neuronal and synaptic transmission through the interference with ion channels in the neuronal membrane. Such interference provokes a hyper-polarisation of the neuronal membrane and therefore inhibits post-synaptic neuronal excitability (Khan, Hayes, and Buggy 2014). The mechanism by which ion channels regulate the polarisation of the neuronal membrane and the transmission of the electric signal through the synapses is an evolutionary conserved one. This means not only that it is general to human beings and mammals, but also to the majority of other animals. Moreover, it behaves similarly in all of them. This is different from the case of most anti-proliferative drugs, which target specific mechanisms for aberrant proliferation in certain types of cancers. Given that IAs interfere with such a universal (and foundational) mechanism, issues about dissimilarity or irregularity would not be very worrying. It could then be inferred with a margin of safety that they will work at least to some extent in the patient.

Problems (ii) and (iii), however, would still be relevant. The prediction, indeed, is based on only a part of the mechanism of action (problem ii). IAs are gasses and their interference at the neuronal level requires that they are first dissolved in the blood and distributed. An obese patient has larger fat compartments and IA is highly absorbed and slowly released from the fat tissue. This means that the same dose of IA would work differently in the target patient than in a patient with a normal weight. Thus, even though one can predict *that* the anaesthetic will work based on knowledge of a part of the mechanism, predicting more specifically *how* it will work (e.g., for how long) requires knowledge about other aspects of the mechanism of action. In the same way, there might be some other mechanisms present in this patient which are still unknown but nonetheless influence the way IA works in this case (problem iii).

The reliability of a confirming mechanism-based prediction about efficacy depends on the comprehensiveness of our mechanistic knowledge and the accuracy of the comparison between relevant mechanisms. This is the case even when some involved mechanisms are general or conserved. Nevertheless, there is never certainty about how comprehensive our mechanistic knowledge is. In sum, when there is clinical evidence that a certain intervention works for a certain patient group, and even when the specific patient shares relevant mechanisms (or parts of them) with the patient group, clinicians should still pay close attention.<sup>3</sup> In order to establish with confidence the efficacy of a treatment in a patient, evidence of mechanisms should be complemented by other kinds of evidence. This could be, for instance, evidence about particular aspects of the specific patient and/or her context, as well as additional evidence of difference-making from similar patients.

### ***3.2 Disconfirming predictions about efficacy***

Evidence of mechanisms may also disprove the extrapolation of an efficacy claim from a population study to a particular patient. The disconfirming role of evidence of mechanisms in predictions about efficacy could be characterised as follows: if the relevant mechanisms at work

in the study population and the patient differ in relevant aspects, it can be concluded that the intervention will not produce the targeted effect in the patient.

The difficulties faced by the confirming role of evidence of mechanisms in predictions about efficacy are less challenging for the disconfirming role.

- i In the disconfirming scenario it is not necessary to specify the degree of similarity between the relevant mechanisms in the study population and the patient. It is only required to identify (at least) one relevant difference between them. This is a more feasible task, which can generally be carried out with available procedures. Consider, for instance, comparative process tracing (Steel 2008): the procedure of carefully analysing the relevant mechanisms in the study population and, subsequently, comparing them with mechanisms at work in the target in (some of) those stages in which they are likely to differ. Adopting comparative process tracing may result in the identification of relevant differences between the relevant mechanisms present in the study population and in the patient.
- ii Even if our knowledge about the relevant mechanisms in the study population and the patient is fragmentary, it is possible to identify a relevant difference between them. Note that the identification of all the relevant differences is not required in disconfirming mechanism-based predictions.
- iii Although unknown interfering mechanisms may be present in the patient, it is unlikely the case that the causal relation holds (despite the identified difference(s)) because of them. The presence of interfering mechanisms in the patient would only enable the causal relation if they operated so that they exactly compensated for the identified difference—i.e., if they ‘restored’ the similarity. However, given the complexity of most biological mechanisms, that exact counterbalance is highly unlikely (Andersen 2012; Howick 2011b; Howick et al. 2010). The interfering mechanisms would probably modify the effect of the intervention, but not compensate exactly for the identified difference.
- iv Mechanisms may not behave in the patient as they do in the study population, but those mechanisms’ absence of regularity would hardly produce that the causal relation holds (despite the identified difference(s)). The irregular behaviour of a mechanism would only enable the causal relation if it operated so that it compensated exactly for the identified difference. Nevertheless, as in the case of masking, that exact counterbalance is highly unlikely given the complexity of biological mechanisms. The irregular behaviour would probably just result in a different untargeted effect.

The disconfirming role of evidence of mechanisms is not undermined by the problems usually encountered in mechanism-based predictions about efficacy. Therefore, once we identify a relevant difference between the mechanisms present in the patient and the mechanism of action by which the intervention works in the study population, we have a solid ground to predict that the intervention’s efficacy will be hindered in the patient.

In order to illustrate the disconfirming role of evidence of mechanisms in predictions about efficacy, consider the following example about botulinum. Botulinum toxins cause flaccid paralysis (by interfering with vesicle fusion and neurotransmitter release in the neuronal cells) and are used to treat many conditions (Chen 2012). Although they interfere with an evolutionary conserved mechanism, many other factors influence the therapeutic action, such as age, type, and stage of the illness; thus, it is usually difficult to predict whether a particular patient will respond positively and which doses will work for her (see subsection 3.1) (Misra et al. 2012). Nevertheless, in cases of long-term therapy, some patients develop neutralising antibodies against

the protein, which diminish or counteract the therapeutic effect (Torres et al. 2014). The presence of neutralising antibodies is evidence for a relevant difference between the mechanism present in the study population (where botulinum toxins produce the effect) and the mechanism present locally. Consequently, even though many components of the mechanisms at work in a particular patient are always unknown, and even though there is variation in the effects of the neutralising antibodies, once they are found in a patient's blood, it is justified to expect that the therapy will have reduced (or neutralised) efficacy.

#### 4 Predictions about specific side effects

In section 2 we saw that, since predictions about efficacy concern specific effects, they should be treated differently from predictions about safety, which normally include a range of possible undesired effects. But what if the concern is about the risk of a specific side effect? At a biological level, the question 'will this specific effect happen?' seems to be the same, regardless of whether the effect is a desired or an undesired one. Nevertheless, the considerations we made in the previous section do not seem to apply completely in the case of undesired effects. We will illustrate this with an example.

The antiviral abacavir can provoke violent, life-threatening allergic reactions. Population studies have correlated this undesired effect to a certain point mutation of the HLA-B protein (Mallal et al. 2002). Furthermore, the mechanism underlying this correlation has been elucidated: abacavir activates antigen-presenting cells in genetically susceptible individuals, potentially initiating the pathological hypersensitive response (Martin et al. 2007). At present, there are genetic tests available to screen patients, to identify if they carry the mutated version of HLA-B, and, consequently, to indicate if they are susceptible to the undesired reaction.

Take into consideration each of the two scenarios presented above in relation to this undesired allergic reaction. First, if the genetic test shows that the patient does not carry the genetic mutation, the pathological mechanism underlying the population data is missing a key element. We then have a case where evidence of mechanisms is disconfirming. In this case, the clinician has good grounds to believe that this *specific* hypersensitivity reaction will not happen. So far, the reasoning is the same as with regular predictions about efficacy.

Second, say that the genetic screening reveals the patient does carry the mutation: this element of the mechanism (the mutated HLA-B) is the same in the study population and in the patient. Here the evidence plays a confirming role: since relevant elements of the mechanisms are present, we can predict that the allergic reaction will happen in the patient. In principle, because of the problems discussed in subsection 3.1 (e.g., mechanisms' absence of regularity), one should be much less confident about that prediction and unsure about the intensity of the reaction. In this scenario, however, the case differs from predictions about targeted effects. In the present case, the clinician will typically *not* risk the use of abacavir in the patient because the positive genetic test will be considered a sufficient reason to avoid abacavir and look for an alternative therapy.

The main reason for this divergence between targeted and untargeted effects is that, in general, evidence of mechanisms is given more weight when predicting undesired effects than when predicting efficacy for desired effects (Osimani 2013). This is due to both epistemological and ethical considerations.

In predictions about the particular side effects of treatments, the available evidence is usually scarce. Firstly, randomized controlled trials (RCTs) cannot be designed for testing undesired effects, primarily for ethical reasons, but also due to other limitations. For instance, the limited time span of experiments cannot register long-term side effects. And secondly, evidence about potential harm from large population studies, such as cohorts, is often unavailable, especially for new or relatively new treatments. What clinicians often have available as evidence

of potential harm are case-reports, case-series, case-control studies, and evidence of statistical disproportionality in the databases of spontaneous reports of side-effects (Norén, Hopstadius, and Bate 2013). Therefore, evidence of mechanisms plays a crucial role in predictions about side effects and, accordingly, a significant weight is given to it.

In addition to those general epistemological considerations, there are also some important value choices in place. When a possible treatment for a patient is evaluated, depending on the type and magnitude of the effects and symptoms, clinicians might be more concerned about predictions about untargeted effects rather than targeted effects, or vice versa. When clinicians are concerned about avoiding a lethal side effect (and less concerned about producing the targeted effect), they will likely give more weight to evidence for the existence of mechanisms that produce the side effect (and will also demand more from evidence in support of the existence of mechanisms producing the targeted effect).

Consider the abacavir example again. The identification of important similarities between the study population and the patient, as regards the relevant mechanisms for a potentially fatal side effect, is enough evidence for the clinician to avoid that treatment, regardless of the fact that mechanisms could be masked or behave irregularly. Although mechanism-based confirming predictions about a specific effect have a bigger margin of uncertainty than the disconfirming ones, this uncertainty may be counterbalanced by the magnitude of risk at stake or the relevance of the targeted effect.

## **5 Predictions about safety**

In this section, we will analyse in detail the confirming and the disconfirming role of evidence of mechanisms in predictions about safety. The confirming role refers to cases in which mechanistic knowledge supports predictions about the presence of side effects, while the disconfirming role refers to cases in which mechanistic knowledge supports predictions about the absence of side effects.

When we predict the safety of an intervention for a single patient, based on a population study, and we use mechanistic knowledge to help with that prediction, we face a situation that seems to be the opposite of the predictions about efficacy. In predictions about efficacy, the disconfirming scenario was less demanding (i.e., it required less information about the relevant mechanisms). One needed only to identify one relevant difference between the mechanisms at work in the study population and those in the patient in order to doubt a positive outcome. However, in the more demanding scenario confirming efficacy, one had to establish a high degree of similarity (i.e., the absence of any relevant difference) between the mechanisms in place. The situation is reversed in predictions about side effects, as the less demanding scenario is the confirming one. To confirm a lack of safety, one needs to identify only one mechanism in the patient through which the intervention produced side effects in the study population. However, here the disconfirming case is more demanding and requires corroborating the absence of all the mechanisms through which the intervention produces side effects in the study population.

We will now consider the two scenarios in detail. As in section 3, we will first consider the more problematic case.

### ***5.1 Disconfirming predictions about safety***

Evidence of mechanisms may support the extrapolation of a safety claim—i.e., absence of relevant side effects—from a population study (be it an observational study, a case series, or even a single case report) to a particular patient. The disconfirming role of evidence of mechanisms in predictions about safety could be characterised as follows: if the mechanism(s) through which a



certain intervention produces side effects in the study population is absent in the patient, it can be concluded that the intervention will not produce side effects and is safe for that patient.

The disconfirming role of evidence of mechanisms in predictions about safety has important problems.

- i It is sometimes impossible to corroborate the absence of certain mechanisms (due to ethical or technical reasons). Consequently, it can be the case that the presence of some known mechanisms through which an intervention produces side effects in the study population cannot be ruled out. For instance, consider psychological mechanisms, which can lead to the abuse of some types of drugs and to addiction. Psychological mechanisms cannot be mapped biomedically; their identification relies exclusively on clinical dialogue, the collaboration and compliance of the patient, and the clinician's skills and availability. Therefore, when these resources are absent, the presence of relevant psychological mechanisms in the patient cannot be ruled out.
- ii In a case where, in principle, the absence of every known relevant mechanism can be tested (no problem i), their number or the resources required for testing could make it unfeasible in the relevant contexts. One vaccine against the Dengue virus, for instance, can paradoxically provoke a deadly Dengue infection if it is given to patients who have never been infected by a sub-family of the Dengue virus before (the first Dengue infection is generally light and unnoticed). This is due to a mechanism called 'antibody-dependent enhancement'. In order to make sure that this mechanism is not present in the patient, it is necessary to verify before the vaccination that she has antibodies against one of the four subtypes of Dengue virus in her blood. However, Dengue is endemic in developing countries, where the technical and economic resources for such a blood test in every child are unavailable and almost unthinkable (Sridhar et al. 2018).
- iii There may be unknown mechanisms through which an intervention produces side effects in the study population. Even if the absence of all the known relevant mechanisms in the patient can be corroborated (no problems i and ii), it can still be the case that mechanisms through which the intervention produces side effects in the study population are present in her. Consequently, we can hardly be sure that the premise of the disconfirming-scenario prediction is met.

Consider the following example about the drug warfarin. Warfarin is an anticoagulant drug (used to prevent blood clots) which must be used with extreme caution because an excessive dose can provoke gastrointestinal bleeding and death. One problem related with its use is that many other drugs, foods, and drinks can influence how much and how quickly it is absorbed in the intestine and, in certain cases, produce a deadly interaction. In a specific patient, one can make sure that all the hazardous known interactions are avoided. However, the same side effect (altered absorbing—excess in the blood—internal bleeding and death) can be produced by interactions that are still unknown. This may be the case because this patient has access to a type of food, drink, or spice not commonly used in the observed population, or because the effect and underlying mechanism of the interaction, despite such an interaction being common, have gone unnoticed. Certain common interactions may remain unknown because of the over-determination of the effect by multiple causes. For instance, the fact that grapefruit juice interferes with the intake of many drugs (including warfarin) through the

inhibition of the enzyme cytochrome P450 3A4 (CYP3A4) was unknown until its serendipitous discovery in 1989 (Bailey et al. 1998).

- iv In cases where the patient is not well enough represented by the study population, there may be certain mechanisms through which the intervention produces side effects in that specific patient that are absent in the study population. Thus, even though all the mechanisms through which the intervention produces side effects are identified in the study population (no problem iii), and even though it was corroborated that none of them is present in the patient (no problems i and ii), other hazardous mechanisms could still be present in her. As a consequence, even if the premise of the disconfirming-scenario prediction is met, the intervention could produce relevant side effects.

The possibility of additional hazardous mechanisms is the reason why practitioners are typically reluctant to make predictions about safety from a population study to pregnant women, multi-morbid patients, older patients, and other patient groups usually excluded from clinical studies. Regarding these patient groups, we often have enough knowledge to predict in advance that, given the presence of some specific mechanisms in them, conclusions about safety cannot be directly applied from population studies. Nonetheless, these predictions are not always possible, since some interventions can provoke rare and idiosyncratic reactions in some patients, where it is not easy to say how the patient differs from the rest of the population. For example, some children show a rare and fatal liver reaction to the anti-epileptic drug valproic acid. However, from the 1970s, when it was first marketed, to 2010 it was not possible to predict which children had the propensity to be fatally injured by the drug because the mechanism of interaction in those specific children was unknown (Price et al. 2011). Only after discovering that the drug interacts with a mutated form of the mitochondrial protein POLG, could safety predictions be extrapolated from the frequency of the side effect in populations and applied to the single patient (Sitarz et al. 2014). This and similar examples, once again, show how a lack of mechanistic knowledge can seriously undermine the safe use of drugs.

The disconfirming role of evidence of mechanisms in predictions about safety faces important difficulties. It means that a safety (or absence of side effects) claim can hardly be inferred from a population study to a particular patient exclusively on the basis of evidence of mechanisms. In order to establish a reasonable degree of safety for a patient's treatment, evidence of mechanisms should be complemented by other kinds of evidence. Such evidence could, for instance, come from a thorough mapping and understanding of the patient's specific context.

### ***5.2 Confirming predictions about safety***

Evidence of mechanisms may also support the extrapolation of a claim that a treatment is unsafe—i.e., presence of relevant side effects—from a population study to a particular patient. The confirming role of evidence of mechanisms in predictions about safety could be characterised as follows: if (one or more) mechanisms through which certain intervention produces side effects in the study population are present in the patient, it can be concluded that the intervention will produce side effects and is not safe for the patient.

The confirming role of evidence of mechanisms in predictions about safety is not severely undermined by the problems faced by the disconfirming role.

- i In cases where it is not possible to check the presence of certain mechanisms through which an intervention produces side effects in the study population, it is

often possible to corroborate the presence of other relevant mechanisms in a particular patient. In predictions about safety, we are not concerned about a specific side effect (or hazardous mechanism), but about side effects (or hazardous mechanisms) in general. Therefore, the presence of any relevant mechanism would undermine the safety of the intervention.

- ii Even if, given their large number or the limited resources available, it is unfeasible to check the presence of all the known mechanisms through which an intervention produces side effects in the study population, the presence of some of them in a single patient could be corroborated. It should be noted that often the relevant mechanisms are neither equally expensive nor equally difficult to detect. The identification of some relevant mechanisms would be enough for considering that an intervention is unsafe. The presence of all the mechanisms (and the potential occurrence of all the side effects) is not required to determine it is unsafe.
- iii Although only some mechanisms through which an intervention produces side effects in the study population are known, some of the known hazardous mechanisms could be identified in the single patient. In those cases, despite the fragmentary knowledge about the study population, a risk to the patient's safety can be inferred on the bases of the common relevant mechanisms.
- iv Even if only a part of the mechanisms through which an intervention produces side effects is present in the study population, the study population can provide a reference for corroborating the intervention's risk to a particular patient's safety. Confirming that some of the hazardous mechanisms present in the study population are also present in the patient is enough to suggest that the intervention would produce side effects and is thus not safe for her.

Masking and the absence of regularity in mechanisms, which undermine the confirming role of evidence of mechanisms in predictions about efficacy (see subsection 3.1), are not, however, very problematic in mechanism-based predictions about side effects. Firstly, although unnoticed interfering mechanisms present in the patient could influence the identified hazardous mechanisms and/or their effects, it is unlikely that they would completely mask the identified mechanisms and prevent side effects. They would probably just modify some side effects. And secondly, the identified mechanisms may not behave in the patient as in the study population, but that absence of regularity would hardly prevent the side effects. As in the case of masking, the irregularity would probably just modify some side effects.

The confirming role of evidence of mechanisms in predictions about safety is not undermined by the problems usually faced by mechanism-based predictions. Once some mechanisms through which a certain intervention produces relevant side effects in the study population are identified in a particular patient, it can then be claimed that the intervention would likely produce side effects in the patient and thus not be safe. Further investigations into other hazardous mechanisms or complementary evidence are welcome, but they are not required for making a reliable prediction about the lack of safety.

Consider, for instance, the following example. It might be discovered that a patient is allergic to one of the components of a certain drug formulation, either from previous history or from serological analysis. In that case, it would be justified to conclude that the drug would probably produce an allergic reaction and not be safe for the patient. Obviously, there might be other mechanisms for other side effects, but it would be unfeasible to check for everything. Furthermore, unknown interfering mechanisms or irregular behaviour of known mechanisms could influence the allergic reaction. Nonetheless, the knowledge already available is enough to infer that the patient is likely to experience an allergic reaction against the drug.

## **6 Conclusion**

Evidence of mechanisms contributes significantly to decision-making in the clinical practice. Nevertheless, its reliability and the support it gives to predictions about the relevant outcomes of interventions may vary considerably. In order to clarify the contribution of evidence of mechanisms to clinical reasoning, we have identified and analysed the different roles that it can play in predictions about efficacy and in predictions about safety. In regard to predictions about efficacy, we have argued that evidence of mechanisms is more reliable for determining that an intervention would not produce a specific (target or untargeted) effect in a patient and less reliable for establishing that it would produce the effect. With regard to predictions about safety we have, on the contrary, argued that evidence of mechanisms is more reliable for establishing that an intervention would produce side effects and thus not be safe for a patient, and less reliable for determining its safety.

Our analysis aims to assist critical reasoning and the evaluation of evidence-based choices in the clinical setting, and thus has important practical implications. It suggests that, generally, evidence of mechanisms is more decisive for discarding inadequate treatments than for identifying suitable ones. Evidence of mechanisms by itself cannot sufficiently establish that an intervention, which was effective or safe in a study population, will be effective or safe for a particular patient. This, of course, does not mean that in these cases evidence of mechanisms should be discarded as useless. Rather, predictions based on this type of evidence should seek further support or, at least, be taken with caution. On the other hand, according to our analysis, evidence of mechanisms can in principle offer a sufficient basis for predicting that an intervention shown to be effective or safe in a study population might not be so for a single patient.

## References

- Andersen, H. 2012. "Mechanisms: What Are They Evidence for in Evidence-based Medicine?" *J Eval Clin Pract* 18 (5): 992–99. <https://doi.org/10.1111/j.1365-2753.2012.01906.x>.
- Bailey, D. G., et al. 1998. "Grapefruit Juice–Drug Interactions." *Br J Clin Pharmacol* 46 (2): 101–10. <https://doi.org/10.1046/j.1365-2125.1998.00764.x>.
- Chen, S. 2012. "Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments." *Toxins* 4 (10): 913–39. <https://doi.org/10.3390/toxins4100913>.
- Clarke, B., et al. 2014. "Mechanisms and the Evidence Hierarchy." *Topoi* 33 (2): 339–60. <https://doi.org/10.1007/s11245-013-9220-9>.
- Giorgi Rossi, P. 2016. "Recommendation without Experts? Epistemological Implications in the Development of Screening Guidelines." *Preventive Medicine* 83: 22–25. <https://doi.org/10.1016/j.ypmed.2015.11.025>.
- Glennan, S. 2017. *The New Mechanical Philosophy*. Oxford, UK: Oxford University Press.
- Howick, J. 2011a. *The Philosophy of Evidence-Based Medicine*. Oxford, UK: Wiley-Blackwell.
- . 2011b. "Exposing the Vanities—and a Qualified Defense—of Mechanistic Reasoning in Health Care Decision Making." *Philos Sci* 78 (5): 926–40. <https://doi.org/10.1086/662561>.
- Howick, J., P. Glasziou, and J. K. Aronson. 2010. "Evidence-Based Mechanistic Reasoning." *J R Soc Med* 103 (11): 433–41. <https://doi.org/10.1258/jrsm.2010.100146>.
- . 2013. "Problems with Using Mechanisms to Solve the Problem of Extrapolation." *Theor Med Bioeth* 34 (4): 275–91. <https://doi.org/10.1007/s11017-013-9266-0>.
- Illari, P. M. 2011. "Mechanistic Evidence: Disambiguating the Russo–Williamson Thesis." *International Studies in the Philosophy of Science* 25 (2): 139–57. <https://doi.org/10.1080/02698595.2011.574856>.
- Illari, P. M., and J. Williamson. 2012. "What Is a Mechanism? Thinking about Mechanisms across the Sciences." *Eur J Philos Sci* 2 (1): 119–35. <https://doi.org/10.1007/s13194-011-0038-2>.
- Khan, K. S., I. Hayes, and D. J. Buggy. 2014. "Pharmacology of Anaesthetic Agents II: Inhalation Anaesthetic Agents." *Continuing Education in Anaesthesia, Critical Care & Pain* 14 (3): 106–11. <https://doi.org/10.1093/bjaceaccp/mkt038>.
- Mallal, S., et al. 2002. "Association between Presence of HLA-B\*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir." *The Lancet* 359 (9308): 727–32. [https://doi.org/10.1016/S0140-6736\(02\)07873-X](https://doi.org/10.1016/S0140-6736(02)07873-X).
- Martin, A. M., et al. 2007. "Immune Responses to Abacavir in Antigen-Presenting Cells from Hypersensitive Patients." *AIDS* 21 (10): 1233–44. <https://doi.org/10.1097/QAD.0b013e3280119579>.
- Misra, V. P., et al. 2012. "Factors Influencing Response to Botulinum Toxin Type A in Patients with Idiopathic Cervical Dystonia: Results from an International Observational Study." *BMJ Open* 2 (3): e000881. <http://dx.doi.org/10.1136/bmjopen-2012-000881>.

- Norén, G. N., J. Hopstadius, and A. Bate. 2013. “Shrinkage Observed-to-Expected Ratios for Robust and Transparent Large-Scale Pattern Discovery.” *Stat Methods Med Res* 22 (1): 57–69. <https://doi.org/10.1177/0962280211403604>.
- Osimani, B. 2013. “Until RCT Proven? On the Asymmetry of Evidence Requirements for Risk Assessment.” *J Eval Clin Pract* 19 (3): 454–62. <https://doi.org/10.1111/jep.12039>.
- Parkkinen, V., et al. 2018. *Evaluating Evidence of Mechanisms in Medicine: Principles and Procedures*. Cham, Switzerland: Springer.
- Pérez-González, S., and V. Iranzo. 2021. “Assessing the Role of Evidence of Mechanisms in Causal Extrapolation.” *THEORIA. An International Journal for Theory, History and Foundations of Science* 36 (2): 211–28. <https://doi.org/10.1387/theoria.21642>.
- Price, K. E., et al. 2011. “Effects of Valproic Acid on Organic Acid Metabolism in Children: A Metabolic Profiling Study.” *Clin Pharmacol Ther* 89 (6): 867–74. <https://doi.org/10.1038/clpt.2011.47>.
- Reiss, J. 2010. “Across the Boundaries: Extrapolation in Biology and Social Science, Daniel P. Steel. Oxford University Press, 2007. Xi + 241 Pages.” *Econ Philos* 26 (3): 382–90. <https://doi.org/10.1017/S0266267110000325>.
- Rocca, E. 2016. “Bridging the Boundaries between Scientists and Clinicians—Mechanistic Hypotheses and Patient Stories in Risk Assessment of Drugs.” *J Eval Clin Pract* 23 (1): 114–20. <https://doi.org/10.1111/jep.12622>.
- Rocca, E., R. L. Anjum, and S. Mumford. 2020. “Causal Insights from Failure: Post-Marketing Risk Assessment of Drugs as a Way to Uncover Causal Mechanisms.” In *Uncertainty in Pharmacology: Epistemology, Methods, and Decisions*, eds. A. LaCaze and B. Osimani, 39–57. Cham, Switzerland: Springer.
- Russo, F., and J. Williamson. 2007. “Interpreting Causality in the Health Sciences.” *International Studies in the Philosophy of Science* 21 (2): 157–70. <https://doi.org/10.1080/02698590701498084>.
- Ruthenberg, K. 2016. “About the Futile Dream of an Entirely Riskless and Fully Effective Remedy: Thalidomide.” *HYLE—International Journal for Philosophy of Chemistry* 22: 55–77. [https://doi.org/10.1142/9789811233548\\_0006](https://doi.org/10.1142/9789811233548_0006).
- Salmon, W. C. 1998. *Causality and Explanation*. Oxford, UK: Oxford University Press.
- Sitarz, K. S., et al. 2014. “Valproic Acid Triggers Increased Mitochondrial Biogenesis in POLG-Deficient Fibroblasts.” *Mol Genet Metab* 112 (1): 57–63. <https://doi.org/10.1016/j.ymgme.2014.03.006>.
- Sridhar, S., et al. 2018. “Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.” *N Engl J Med* 379 (4): 327–40. <https://doi.org/10.1056/NEJMoa1800820>.
- Steel, D. 2008. *Across the Boundaries: Extrapolation in Biology and Social Science*. Oxford, UK: Oxford University Press.
- Tonelli, M. R., and J. Williamson. 2020. “Mechanisms in Clinical Practice: Use and Justification.” *Med Health Care Philos* 23 (1): 115–24. <https://doi.org/10.1007/s11019-019-09915-5>.
- Torres, S., et al. 2014. “Neutralizing Antibodies to Botulinum Neurotoxin Type A in Aesthetic Medicine: Five Case Reports.” *Clin Cosmet Investig Dermatol* 7: 11–17. <https://doi.org/10.2147/CCID.S51938>.

Van Eersel, G. G., G. V. Koppenol-Gonzalez, and J. Reiss. 2019. "Extrapolation of Experimental Results through Analogical Reasoning from Latent Classes." *Philos Sci* 86 (2): 219–35. <https://doi.org/10.1086/701956>.

Williamson, J. 2019. "Establishing Causal Claims in Medicine." *International Studies in the Philosophy of Science* 32 (1): 33–61. <https://doi.org/10.1080/02698595.2019.1630927>.

## Notes

<sup>1</sup> For a detailed discussion on the nature of mechanisms in science, see (Glennan 2017).

<sup>2</sup> Note that by ‘relevant’ here we mean ‘relevant given the known mechanism of action’.

<sup>3</sup> It should be noted that this is not necessarily an argument to discourage the use of evidence of mechanisms in clinical practice. Rather, it can be understood as an argument for an increased alert and effort to constantly improve and expand mechanistic understanding. Notice that, in the cases in which we make a wrong prediction and the intervention does not work as expected, we have the chance to investigate the reason of failure and improve our mechanistic knowledge (Rocca 2016; Rocca, Anjum, and Mumford 2020).